Snowman Research
US orders ship free, any size.

Free US shipping on every order · Worldwide for $40 · Usually ships within 24 hours, with tracking provided

Sermorelin vs tesamorelin vs CJC-1295 (no DAC)

Sermorelin, tesamorelin and CJC-1295 are all modeled on growth hormone-releasing hormone (GHRH), but they are built differently and have very different regulatory histories. Ipamorelin, which shares a vial with CJC-1295 on our shelf, is not a GHRH analog at all. This guide covers structure and status only: no dosing, no outcomes.

Snowman Research does not offer dosing information or usage guidance of any kind. Everything on this page is reference material about research products sold for laboratory research only.

Three GHRH analogs
SermorelinTesamorelinCJC-1295 (no DAC)
Relation to GHRHThe first 29 amino acids of GHRH: GHRH (1-29)[1]An analog of full-length GHRH (growth hormone-releasing factor), modified at its N-terminus[3]A modified GRF (1-29), a GHRH analog
As we stock itAcetate salt, 5mg vial5mg vial5mg, paired with 5mg ipamorelin in one vial
U.S. regulatory historyGEREF (sermorelin acetate) was approved in 1990 and 1997 and discontinued in 2008; the FDA found it was not withdrawn for reasons of safety or effectiveness[2]Approved in 2010; today's prescribing label covers a single use. This research material is distinct from that medicine[3]Listed on the FDA's compounding-risk page among substances formerly in category 2 whose nominations were withdrawn[5]
WADA 2026 ListSection S2.2.4 (GHRH analogues)[6]Section S2.2.4, listed by name[6]Section S2.2.4 (GHRH analogues)[6]

What "no DAC" means here

Published human pharmacology for CJC-1295 describes a long-acting version that attaches to albumin once administered[4]. The vial we stock is labeled "without DAC", so findings for the albumin-binding version should not be assumed to transfer to it.

Where ipamorelin fits

Ipamorelin is a five-residue peptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), introduced in 1998 as a selective growth hormone secretagogue[7]. It works through a different receptor from the three analogs above: it is studied as an agonist of the ghrelin receptor (GHS-R1a), not the GHRH receptor. WADA's 2026 List names it as a GH secretagogue under section S2.2.4[6].

On our shelf

Sources

  1. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-57. PMID 18031173. https://pubmed.ncbi.nlm.nih.gov/18031173/
  2. Determination That GEREF (Sermorelin Acetate) Injection ... Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. FDA notice, Federal Register 78 FR 14095 (Mar 4, 2013). https://www.govinfo.gov/content/pkg/FR-2013-03-04/html/2013-04827.htm
  3. DailyMed - EGRIFTA WR (tesamorelin) prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  4. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7. PMID 17018654. https://pubmed.ncbi.nlm.nih.gov/17018654/
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. U.S. Food and Drug Administration, human drug compounding web page (accessed Oct 4, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  6. World Anti-Doping Code International Standard: Prohibited List 2026 (in effect 1 January 2026). World Anti-Doping Agency. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
  7. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PMID 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/

For laboratory research use only. Not for human or veterinary use, not FDA-approved, and nothing on this page is medical advice. You must be 21 or older to purchase.